Reversible very late onset myasthenia gravis following intravesical Bacillus Calmette-Guerine treatment: a case report

Giacomo Bavestrello , Marina Grandis , Marco Borghesi , Elena Faedo , Carolina Barone , Sara Massucco , Lucio Marinelli

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004169

PDF (2666KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004169 DOI: 10.37349/ent.2026.1004169
Case Report
research-article
Reversible very late onset myasthenia gravis following intravesical Bacillus Calmette-Guerine treatment: a case report
Author information +
History +
PDF (2666KB)

Abstract

Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder occasionally triggered by immunomodulatory therapies. While immune checkpoint inhibitors are well-recognized culprits, traditional antineoplastic treatments like intravesical Bacillus Calmette-Guerine (BCG) can also precipitate severe immune-related adverse events. We describe a rare presentation of BCG-induced MG, emphasizing the crucial diagnostic role of clinical neurophysiology in evaluating atypical focal onset. A 76-year-old male with high-grade urothelial carcinoma underwent transurethral resection followed by a standard six-week induction of intravesical BCG. Twelve days after the final instillation, he developed isolated, severe neck extensor weakness resulting in dropped head syndrome (antecollis). Following an unrevealing cervical magnetic resonance imaging scan and the failure of empirical conservative management, a comprehensive neurophysiological evaluation was strictly performed. Concentric needle electromyography of the splenius capitis muscle revealed focal myopathic alterations, including early recruitment of small motor unit potentials, positive sharp waves, and fibrillation potentials. Crucially, low-frequency repetitive nerve stimulation (RNS) of the spinal accessory nerve, recording from the trapezius, demonstrated a significant, diagnostic decremental response of the compound muscle action potential amplitude. Serological assays confirmed highly elevated anti-acetylcholine receptor antibodies. Chest computed tomography excluded thymoma, establishing the diagnosis of very late-onset generalized MG (MGFA class IIb). Initial symptomatic monotherapy with pyridostigmine lacked efficacy. However, targeted therapy combining oral prednisone (0.5 mg/kg/day) and pyridostigmine induced a dramatic, rapid resolution of the antecollis and subsequent dysphagia. Corticosteroids were progressively tapered and definitively discontinued after six months, achieving sustained clinical remission without relapses. We report the third formally documented case of very late-onset generalized MG triggered by intravesical BCG immunotherapy, hypothetically mediated by pathogenic epitope sharing between mycobacterial and self-antigens. This case distinctly highlights the pivotal diagnostic utility of RNS in differentiating acute atypical axial weakness. Furthermore, it demonstrates that BCG-induced MG exhibits a highly favourable, fully reversible prognosis following prompt, targeted corticosteroid intervention.

Keywords

head drop / anti-acetylcholine receptor antibodies / BCG / bladder cancer / repetitive nerve stimulation / neuromuscular junction / case report

Cite this article

Download citation ▾
Giacomo Bavestrello, Marina Grandis, Marco Borghesi, Elena Faedo, Carolina Barone, Sara Massucco, Lucio Marinelli. Reversible very late onset myasthenia gravis following intravesical Bacillus Calmette-Guerine treatment: a case report. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004169 DOI:10.37349/ent.2026.1004169

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Lehnerer S, Stegherr R, Grittner U, Stein M, Gerischer L, Stascheit F, et al. The burden of disease in seronegative myasthenia gravis: a patient-centered perspective. Front Immunol. 2025; 16: 1555075.

[2]

Behin A, Le Panse R. New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis. J Neuromuscul Dis. 2018; 5: 265-77.

[3]

Pasnoor M, Wolfe GI, Barohn RJ. Myasthenia gravis. Handb Clin Neurol. 2024; 203: 185-203.

[4]

Cortés-Vicente E, Álvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020; 94: e1171-80.

[5]

Liampas I, Veltsista D, Batzikosta P, Lazarou L, Kefalopoulou ZM, Chroni E. The short-term prognosis of very late onset generalized myasthenia gravis: a single-center retrospective cohort study. Front Neurol. 2025; 16: 1641701.

[6]

Sheikh S, Alvi U, Soliven B, Rezania K. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J Clin Med. 2021; 10: 1537.

[7]

Preston DC, Shapiro BE, editors. Electromyography and neuromuscular disorders, 4th edition. Philadelphia: Elsevier; 2021.

[8]

Oguz-Akarsu E, Lazrak SEH, Gullu G, Dinç Y, Saridas F, Karli N. Unusual presentations of myasthenia gravis and misdiagnosis. Sci Rep. 2025; 15: 7516.

[9]

Locht C, Lerm M. Good old BCG-what a century-old vaccine can contribute to modern medicine. J Intern Med. 2020; 288: 611-3.

[10]

Anis O, Yogev D, Dotan A, Tsur AM, David P, Vishnevskia Dai V, et al. Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: A systematic review. Autoimmun Rev. 2023; 22: 103329.

[11]

Takizawa T, Kojima M, Suzuki S, Osada T, Kitagawa S, Nakahara J, et al. New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin: A case report and literature review. Medicine (Baltimore). 2017; 96: e8757.

[12]

Davalos L, Kushlaf H. New onset of seropositive generalized myasthenia gravis following intravesical bacille Calmette-Guerin treatment for bladder cancer: A case study. Muscle Nerve. 2019; 59: E1-2.

[13]

Jing F, Cui F, Chen Z, Yang F, Ling L, Huang X. Clinical and Electrophysiological Markers in Myasthenia Gravis Patients. Eur Neurol. 2015; 74: 22-7.

[14]

Ricciardi R, Latini E, Guida M, Koneczny I, Lucchi M, Maestri M, et al. Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients. J Neurol Sci. 2024; 461: 123047.

[15]

Lalwani CS, Movva H, Kannoth S, Nambiar V, Gopinath S, Anandakuttan A, et al. Clinical Characteristics of Double Seropositive Myasthenia Gravis. Neurol India. 2024; 72: 1066-9.

PDF (2666KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉